 |
|
Firefly protein lets researchers monitor molecule linked to cancer
August 10, 2005Scientists have used a glowing protein from fireflies to observe the activity of a molecule that is an important target for new drugs to treat cancer, autoimmune diseases and several other disorders.
The target molecule, known as IKK (for IKappa kinase), regulates processes that can trigger dramatic changes in cellular physiology. Scientists have linked these changes to many different disorders.
"Our new system allows researchers to monitor whether drugs for these conditions are hitting this exact molecular target in cell culture and laboratory animals," says senior investigator David Piwnica-Worms, M.D., Ph.D., professor of molecular biology and pharmacology and of radiology.
Piwnica-Worms and lead author Shimon Gross, Ph.D., a postdoctoral fellow, measured light from the firefly protein, luciferase, to monitor IKK activity in tumor cells and inflamed liver cells in live mice. They also showed that the technique can greatly reduce the costs of tests that establish the best dosages for drugs that target IKK. Their results appear in the August 2005 issue of Nature Methods.
IKK stands at a pivot point in the middle of an important set of linked chain reactions known as the NF-KappaB pathway. The pathway can start at many different receptors on cell surfaces; its finish changes the activity levels of varying genes. The result, according to Piwnica-Worms, is that the potential reaction patterns in the NF-KappaB pathway form an hourglass-like shape, fanning out among many options at the start, narrowing in the middle, and again fanning out among many options at the end.
"At the waist of that hourglass is IKK," he explains. "This appears to put it in a position to be the key regulator of the pathway, and that has made it a subject of great interest both from the perspective of understanding how this pathway works and from that of developing new drugs for conditions that involve this pathway. "
Piwnica-Worms' laboratory has previously developed techniques that use luciferase to monitor protein-protein interactions. Researchers can employ an instrument known as an in-vivo bioluminescence camera to take real-time measurements of light from luciferase in cell cultures and in cells within live animals.
To use the firefly protein to monitor IKK, Gross altered cell lines to genetically fuse the luciferase protein to IKB (IKappaB), the protein that comes immediately after IKK in the NF-KappaB pathway. When the pathway is enabled, IKK triggers reactions that lead to the degradation of IKB. In cells with genetically altered IKB, the attached luciferase is broken down too, meaning scientists can detect increased IKK activity via decreased light from the cells.
"This is like doing in-vivo pharmacodynamics and pharmacokinetics," says Piwnica-Worms in reference to the sciences that study the effects, distribution and dissipation of drugs. "Traditionally the only ways we could do those kinds of studies were either to test for levels of the drug in the blood or to label the drug with a radioactive tracer.
"In the case of NF-KappaB, there were also methods that monitored IKK activity via changes in the levels of gene activation at the end of the pathway," he notes. "But those took hours to days to deliver results, and our approach works continuously and in real time."
In their study, Gross and Piwnica-Worms tested the technique in live mice by transplanting genetically altered tumor cells and by using a technique that inserted the fused IKB/luciferase protein into liver cells only. They are currently working to develop a line of mice with the IKB/luciferase fusion built into its genetic code.
In addition, they showed that the system is not only helpful for learning if a drug is having the desired effect, it can also be used to fine-tune drug dosage for maximum benefit.
"One of the reviewers of our paper suggested that we should use the system to produce a full dose-response curve, which helps establish how to best use a drug," Piwnica-Worms says. "Establishing that normally takes 6 months and 300 mice. With our monitoring technique, Shimon did it in a 5-day period using 30 mice. That's going to lead to tremendous cost savings.\\\
Washington University School of Medicine
Piwnica-Worms and lead author Shimon Gross, Ph.D., a postdoctoral fellow, measured light from the firefly protein, luciferase, to monitor IKK activity in tumor cells and inflamed liver cells in live mice. They also showed that the technique can greatly reduce the costs of tests that establish the best dosages for drugs that target IKK. Their results appear in the August 2005 issue of Nature Methods.
IKK stands at a pivot point in the middle of an important set of linked chain reactions known as the NF-KappaB pathway. The pathway can start at many different receptors on cell surfaces; its finish changes the activity levels of varying genes. The result, according to Piwnica-Worms, is that the potential reaction patterns in the NF-KappaB pathway form an hourglass-like shape, fanning out among many options at the start, narrowing in the middle, and again fanning out among many options at the end.
"At the waist of that hourglass is IKK," he explains. "This appears to put it in a position to be the key regulator of the pathway, and that has made it a subject of great interest both from the perspective of understanding how this pathway works and from that of developing new drugs for conditions that involve this pathway. "
Piwnica-Worms' laboratory has previously developed techniques that use luciferase to monitor protein-protein interactions. Researchers can employ an instrument known as an in-vivo bioluminescence camera to take real-time measurements of light from luciferase in cell cultures and in cells within live animals.
To use the firefly protein to monitor IKK, Gross altered cell lines to genetically fuse the luciferase protein to IKB (IKappaB), the protein that comes immediately after IKK in the NF-KappaB pathway. When the pathway is enabled, IKK triggers reactions that lead to the degradation of IKB. In cells with genetically altered IKB, the attached luciferase is broken down too, meaning scientists can detect increased IKK activity via decreased light from the cells.
"This is like doing in-vivo pharmacodynamics and pharmacokinetics," says Piwnica-Worms in reference to the sciences that study the effects, distribution and dissipation of drugs. "Traditionally the only ways we could do those kinds of studies were either to test for levels of the drug in the blood or to label the drug with a radioactive tracer.
"In the case of NF-KappaB, there were also methods that monitored IKK activity via changes in the levels of gene activation at the end of the pathway," he notes. "But those took hours to days to deliver results, and our approach works continuously and in real time."
In their study, Gross and Piwnica-Worms tested the technique in live mice by transplanting genetically altered tumor cells and by using a technique that inserted the fused IKB/luciferase protein into liver cells only. They are currently working to develop a line of mice with the IKB/luciferase fusion built into its genetic code.
In addition, they showed that the system is not only helpful for learning if a drug is having the desired effect, it can also be used to fine-tune drug dosage for maximum benefit.
"One of the reviewers of our paper suggested that we should use the system to produce a full dose-response curve, which helps establish how to best use a drug," Piwnica-Worms says. "Establishing that normally takes 6 months and 300 mice. With our monitoring technique, Shimon did it in a 5-day period using 30 mice. That's going to lead to tremendous cost savings.\\\
Washington University School of Medicine
New Drugs Current Events and New Drugs News RSSFood for thought -- regulating energy supply to the brain during fasting
If the current financial climate has taught us anything, it's that a system where over-borrowing goes unchecked eventually ends in disaster. It turns out this rule applies as much to our bodies as it does to economics. Instead of cash, our body deals in energy borrowed from muscle and given to the brain.
Many receptor models used in drug design may not be useful after all
It may very well be that models used for the design of new drugs have to be regarded as impractical. This is the sobering though important conclusion of the work of two Leiden University scientists published in Science this week.
Scientists unmask key HIV protein, open door for more powerful AIDS drugs
University of Michigan scientists have provided the most detailed picture yet of a key HIV accessory protein that foils the body's normal immune response.
Discovery offers new understanding of diabetes drug target
Scientists at the University of Leicester have published findings about a new advance in the study of major diabetes drug target.
Bleeding gums linked to heart disease
Bad teeth, bleeding gums and poor dental hygiene can end up causing heart disease, scientists heard today (Thursday 11 September 2008) at the Society for General Microbiology's Autumn meeting being held this week at Trinity College, Dublin.
Study: Delaying evolution of drug resistance in malaria parasite possible
There's no magic bullet for wiping out malaria, but a new study offers strong support for a method that effectively delays the evolution of drug resistance in malaria parasites, a University of Florida researcher says.
Low levels of brain chemical may lead to obesity, NIH study of rare disorder shows
A brain chemical that plays a role in long term memory also appears to be involved in regulating how much people eat and their likelihood of becoming obese, according to a National Institutes of Health study of a rare genetic condition.
New role for Natural Killers!
Scientists at the University of York have discovered a new role for a population of white blood cells, which may lead to improved treatments for chronic infections and cancer.
Variation of normal protein could be key to resistance to common cancer drug
Researchers at the Moores Cancer Center at the University of California, San Diego (UC SD) in La Jolla have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug.
Potential new targets for antidepressant medications
The news about antidepressant medications over the past several years has been mixed. The bad news from large multicenter studies such as STAR*D is that current antidepressant medications are effective, but not as effective as one might hope. Thus, there is a significant need for new treatment mechanisms for depression.
More New Drugs Current Events and New Drugs News Articles
 | The Drug of the New Millennium - The Brain Science Behind Internet Pornography Use by Mark B. Kastleman "Kastleman has presented a masterful analysis of how pornography destroys the mental and spiritual capacity of its victim. I recommend this outstanding book to all parents, educators and religious leaders." - John L. Harmer, former Lieutenant Governor of California under Ronald Regan 3 Power Principles Guaranteed to Protect Your Family Free CD Enclosed "Protecting Your... |
| New Drug Development: A Regulatory Overview by Mark Mathieu | |
 | The Addiction Workbook: A Step-By-Step Guide to Quitting Alcohol and Drugs (New Harbinger Workbooks) by Patrick Fanning, John Terence O'Neill At any given time there are 18 million adult alcoholics and drug addicts in America. Of the 17 percent who quit each year, most do so on there own, Now, this life-changing handbook helps addicts understand their addiction and the negative effect it has on their lives. Using questionnaires and other tools to guide readers toward self-discovery, it provides the steps addicts must take to become... |
 | The $800 Million Pill: The Truth behind the Cost of New Drugs by Merrill Goozner Why do life-saving prescription drugs cost so much? Drug companies insist that prices reflect the millions they invest in research and development. In this gripping exposé, Merrill Goozner contends that American taxpayers are in fact footing the bill twice: once by supporting government-funded research and again by paying astronomically high prices for prescription drugs. Goozner demonstrates... |
 | When Panic Attacks: The New, Drug-Free Anxiety Therapy That Can Change Your Life by David D. Md Burns Are you plagued by fears, phobias, or panic attacks? Do you toss and turn at night with a knot in your stomach, worrying about your job, your family, work, your health, or relationships? Do you suffer from crippling shyness, obsessive doubts, or feelings of insecurity?What you may not realize is that these fears are almost never based on reality. Anxiety is one of the world’s oldest cons. When... |
| The Clinical Evaluation of New Drugs by S O & Alvin P Shapiro MDs Waife | |
 | Clublife: Thugs, Drugs, and Chaos at New York City's Premier Nightclubs by Rob The Bouncer "I've always maintained highly ingrained, stringent standards of right and wrong. Repulsed by much of what I've seen while working as a bouncer, my indignation has served to grant me a particularly keen insight into a rarely seen segment of life in New York. This 'code' by which I've chosen to live, at least in my professional life, has given me a unique perspective on human behavior, as seen... |
 | New Drug Approval Process, Fourth Edition, Accelerating Global Registrations (Drugs and the Pharmaceutical Sciences) Offering expert guidance on the clinical, regulatory, and statistical processes involved in the development of new pharmaceutical product applications for drugs, biologicals, and medical devices, the Fourth Edition details the specific regulations, guidelines, and procedures that will advance and ensure approval of United States and global new product applications. It communicates and integrates... |
 | Potter's New Cyclopaedia of Botanical Drugs and Preparations by R.C. Wren Every plant with a known medicinal use is... |
 | Leary on Drugs: New Material from the Archives! Advice, Humor and Wisdom from the Godfather of Psychedelia by Timothy Leary He famously exhorted people to "turn on, tune in, and drop out," but Timothy Leary had a lot more to say about drugs — a lot more. Leary on Drugs compiles every interesting thing he ever said about the subject. Drawing from Leary’s books, interviews, magazine articles, and scholarly journals, the book includes essays, quotes, and stories, ranging from his first acid trip and the sociology of... |
| © 2008 BrightSurf.com |